REGN

Regeneron Pharmaceuticals, Inc. - Q1 2006 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2006. Regeneron is a biopharmaceutical company focused on discovering and developing products for serious medical conditions. The company has no commercial products currently on the market and relies on contract research, contract manufacturing, and collaboration agreements (notably with sanofi-aventis) for revenue. The company maintains a cumulative deficit since its inception in 1988.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by $2.0 million (12.4%) year-over-year. This was driven by a $4.1 million increase in contract research revenue from sanofi-aventis and a $0.9 million increase in contract manufacturing revenue from Merck. Revenue from Procter & Gamble ceased in Q1 2006 following the expiration of their agreement in June 2005.
• Widened Net Loss: Net loss increased significantly to $20.4 million from $4.1 million in Q1 2005. The prior year period included a one-time $25.0 million non-recurring payment from sanofi-aventis recognized as "Other contract income," which is absent in the current period.
• Expense Reduction: Total operating expenses decreased to $39.9 million from $44.5 million, primarily due to a reduction in headcount (average 587 employees in Q1 2006 vs. 734 in Q1 2005) resulting from workforce reductions initiated in late 2005.
• Accounting Change: The company adopted SFAS 123R effective January 1, 2006. This resulted in a cumulative effect adjustment that reduced the reported net loss by $0.8 million.

Outlook, Guidance, and Risks

• Clinical Pipeline:
  • VEGF Trap (Oncology): Initiated Phase 2 single-agent studies in non-small cell lung adenocarcinoma. Planning additional studies in ovarian cancer and malignant ascites.
  • VEGF Trap-Eye: Initiated a Phase 2 trial for wet Age-Related Macular Degeneration (AMD) following positive Phase 1 results showing reduced retinal thickness and improved visual acuity.
  • IL-1 Trap: Completed enrollment for the pivotal study in CAPS (rare inflammatory diseases); efficacy phase expected to conclude by end of 2006.
• Liquidity and Capital Resources: The company holds approximately $324.2 million in cash, cash equivalents, and marketable securities. Management believes existing resources will fund operations through at least mid-2008. However, the company expects to incur substantial losses for the foreseeable future.
• Key Risks:
  • Dependence on Collaborators: Heavy reliance on sanofi-aventis for funding and commercialization of the VEGF Trap oncology program. Sanofi-aventis can terminate the agreement with 12 months' notice.
  • Revenue Expiration: The contract manufacturing agreement with Merck expires in October 2006, and the Procter & Gamble agreement has already expired, creating a significant revenue gap risk.
  • Debt Obligations: $200 million in convertible notes mature in October 2008 with semi-annual interest payments.
  • Regulatory and Clinical Uncertainty: No products have received regulatory approval; clinical trials are expensive and outcomes are uncertain.

Investor Verification Checklist

• Verify the timeline and funding status of the Phase 2 trials for VEGF Trap-Eye and IL-1 Trap.
• Confirm the status of the Merck contract manufacturing agreement and potential renewal or replacement revenue streams post-October 2006.
• Review the terms of the sanofi-aventis collaboration, specifically the reimbursement obligations for development expenses if the collaboration becomes profitable.
• Assess the impact of the $200 million convertible debt maturing in 2008 on future liquidity and potential dilution.
• Monitor the progress of the workforce reduction plan and the realization of the projected $8 million in annual cost savings.